Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Flexi Cap Fund median (49 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 31 Oct 2025 – 20 Aug 2026, limited by Parag Parikh Flexi Cap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Parag Parikh Flexi Cap Fund | Nifty 500 |
|---|---|---|
| 31 Oct 2025 | ₹100.00 | ₹100.00 |
| 24 Nov 2025 | ₹100.02 | ₹99.85 |
| 19 Dec 2025 | ₹100.01 | ₹99.86 |
| 12 Jan 2026 | ₹99.92 | ₹99.16 |
| 06 Feb 2026 | ₹99.35 | ₹98.83 |
| 02 Mar 2026 | ₹96.84 | ₹96.31 |
| 27 Mar 2026 | ₹91.57 | ₹88.65 |
| 20 Apr 2026 | ₹97.10 | ₹96.44 |
| 14 May 2026 | ₹95.72 | ₹95.37 |
| 08 Jun 2026 | ₹93.88 | ₹93.52 |
| 02 Jul 2026 | ₹96.25 | ₹98.12 |
| 27 Jul 2026 | ₹95.70 | ₹97.65 |
| 20 Aug 2026 | ₹96.12 | ₹99.17 |
| Metric | PPFAS · Direct · IDCW NAV ₹90.74 Very High risk Unrated | Category median Flexi Cap Fund · 49 funds |
|---|---|---|
| — | +2.34% | |
| — | +12.85% | |
| — | +10.36% | |
| — | +8.08% | |
| -3.88% | +11.66% | |
| -2.68% | — | |
| — | +12.67% | |
| — | +11.75% | |
| — | +9.39% | |
| Risk | ||
| 9.43% | 14.56% | |
| — | 0.38 | |
| — | 0.50 | |
| -10.60% | -33.86% | |
| Nifty 500 | — | |
| — | +0.65% | |
| — | 0.98 | |
| — | 100.2% | |
| — | 97.9% | |
| 0.68% | 0.86% | |
| ₹1,40,660Cr | ₹4,009Cr | |
| Up to 2.00% | — | |
| None | — | |
| ₹1.00K | — | |
| ₹1.00K | — | |
| 30% | 37% | |
| Raj Mehta · 10.6y | — | |
| 31 Oct 2025 | — | |
| 61 | — | |
| 50.5% | — | |
| 6.4% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.